Diffusion Pharmaceuticals (NASDAQ:DFFN) Shares Down 0.4%
Diffusion Pharmaceuticals (NASDAQ:DFFN) Shares Down 0.4%
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) shares dropped 0.4% during mid-day trading on Tuesday . The stock traded as low as $6.26 and last traded at $6.34. Approximately 3,125 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 45,431 shares. The stock had previously closed at $6.36.
Wall Street Analysts Forecast Growth
DFFN has been the subject of several recent research reports. HC Wainwright upgraded Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price target for the company in a research note on Tuesday, August 16th. StockNews.com upgraded Diffusion Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, August 15th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Trading Down 0.2 %
The company has a 50 day moving average of $7.06 and a 200-day moving average of $11.67. The firm has a market capitalization of $12.90 million, a P/E ratio of -0.51 and a beta of 1.53.
Hedge Funds Weigh In On Diffusion Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DFFN. JPMorgan Chase & Co. acquired a new position in Diffusion Pharmaceuticals in the 1st quarter valued at $106,000. Renaissance Technologies LLC raised its holdings in Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock valued at $331,000 after acquiring an additional 101,100 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Diffusion Pharmaceuticals in the 2nd quarter valued at $71,000. 10.25% of the stock is owned by institutional investors and hedge funds.Diffusion Pharmaceuticals Company Profile
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Featured Articles
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- GameStop Stock Just Flashed A Buy Signal
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
周二午盘,纳斯达克的股价下跌了0.4%。该股一度跌至6.26美元,最后报6.34美元。午盘交易中,约有3,125股股票成交,较45,431股的日均成交量下降了93%。该股此前收盘价为6.36美元。
华尔街分析师预测经济增长
DFFN是最近几份研究报告的主题。在8月16日周二的一份研究报告中,HC Wainwright将Diffation PharmPharmticals的评级从中性上调至买入,并为该公司设定了9.50美元的目标价。在8月15日(星期一)的一份研究报告中,StockNews.com将扩散制药公司的评级从“卖出”上调为“持有”。
到达扩散制药公司警报:扩散制药公司股价下跌0.2%
该公司的50日移动均线切入位在7.06美元,200日移动均线切入位在11.67美元。该公司的市值为1,290万美元,市盈率为-0.51,贝塔系数为1.53。
对冲基金对扩散制药的看法
几家对冲基金和其他机构投资者最近增持或减持了DFFN的股份。今年第一季度,摩根大通以10.6万美元的价格购入了扩散制药公司的一个新头寸。复兴科技有限责任公司在第一季度增持了8.3%的扩散制药股份。复兴科技有限责任公司在上个季度增持了101,100股后,现在拥有1,324,202股该公司股票,价值331,000美元。最后,Trexquant Investment LP在第二季度收购了扩散制药公司的一个新头寸,价值7.1万美元。10.25%的股票由机构投资者和对冲基金持有。扩散制药公司简介
(获取评级)
扩散制药公司是一家生物制药公司,该公司开发新的疗法,以增强人体输送氧气的能力。它的主要候选产品是反式番茄酸钠,开发这种药物是为了促进氧气向组织的扩散,以及治疗新冠肺炎病。扩散制药公司成立于2001年,总部设在弗吉尼亚州夏洛茨维尔。
专题文章
- 免费获取StockNews.com关于扩散药物的研究报告(DFFN)
- Enphase Energy有没有能力继续往上冲?
- 独一无二的氢燃料电池库存
- 这两只被低估的股票已经做好了进一步冲高的准备
- 化工和化肥库存中是否隐藏着宝藏?
- GameStop股票刚刚闪烁了买入信号
获得《扩散医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对扩散制药及相关公司评级的每日简要摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧